Results 191 to 200 of about 148,501 (250)

Exploring Protein Misfolding in Amyotrophic Lateral Sclerosis: Structural and Functional Insights. [PDF]

Biomedicines
Ivantsik O, Exarchos TP, Vrahatis AG, Vlamos P, Krokidis MG.   +4 more
europepmc   +1 more source

Amyotrophic lateral sclerosis

, 2008
openaire   +1 more source

The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study. [PDF]

Sci Rep
Hu X, Wei M, Zhang H, Yu M, Wang M, Zhou B, Luo Y, Li B.   +7 more
europepmc   +1 more source

Population-Based Versus Hospital-Based Data in Amyotrophic Lateral Sclerosis-A Factor to Consider? [PDF]

Eur J Neurol
Dorst J, Dreyhaupt J, Wernecke D, Weiland U, Parlak Ö, Wiesenfarth M, Elmas Z, Herrmann C, Bäzner H, Boertlein A, Dempewolf S, Foerch C, Hecht M, Kohler A, Opherk C, Althaus K, Clauer-Bredt M, Lindner A, Ruf W, Brenner D, Witzel S, Peter RS, Schuster J, Ludolph AC, Rosenbohm A, Nagel G.   +25 more
europepmc   +1 more source

Impact of sleep quality on disease progression in early-stage amyotrophic lateral sclerosis. [PDF]

Front Neurol
Zhang G, Chen Y, Tang L, Bai L, Zhang H, Liu H, Fan D.   +6 more
europepmc   +1 more source

Remote Monitoring of Amyotrophic Lateral Sclerosis Using Digital Health Technologies: Shifting Toward Digitalized Care and Research? [PDF]

Neurology
van Unnik JWJ, Ing L, Oliveira Santos M, McDermott CJ, de Carvalho M, van Eijk RPA.   +5 more
europepmc   +1 more source

Testosterone Supplementation: A Potential Therapeutic Strategy for Amyotrophic Lateral Sclerosis. [PDF]

Biomedicines
Yang W, Xiao W, Liu X, Li H, Huang T, Fan D.   +5 more
europepmc   +1 more source

Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy. [PDF]

Lancet Neurol
Balendra R, Sreedharan J, Hallegger M, Luisier R, Lashuel HA, Gregory JM, Patani R.   +6 more
europepmc   +1 more source

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

JAMA Netw Open
Paganoni S, Fournier CN, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Ajroud-Driss S, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Shefner JM, Hall M, Kittle G, Berry JD, Babu S, Andrews J, Dagostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Heiman-Patterson T, Caress JB, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Harvey B, Patel S, Mahoney P, Duda PW, Cudkowicz ME, HEALEY ALS Platform Trial Study Group.   +85 more
europepmc   +1 more source